Jeffrey L. Kopacz

Jeffrey L. Kopacz '95 BS serves as Senior Vice-President of Intellectual Property & Agreements at SalioGen Therapeutics, Inc, a gene therapy company located in Lexington, MA.  He oversees corporate legal matters, intellectual property, and agreement work, including building and defending the IP estate for SalioGen’s Gene CodingTM technology and therapeutic candidates.

Previously, he was Vice-President of Intellectual Property Omega Therapeutics, Inc.  He was responsible for most legal matters and all intellectual property and agreement work related to the company’s Precision Epigenomic ControlTM platform and played a key role in guiding Omega to an IPO.  

During a decade at Alnylam Pharmaceuticals, Inc., Jeff was responsible for intellectual property matters related to Alnylam’s clinical and pre-clinical therapeutics, including securing and defending world-wide patent protection for numerous approved RNA interference therapeutics.  

Earlier, he worked at Edwards, Angell Palmer & Dodge (now Locke Lord) and Millennium Pharmaceuticals.

Jeff holds a J.D. from the Suffolk University Law School, a master of science in Molecular Microbiology and Immunology from Johns Hopkins University, and his undergraduate degree in Microbiology from the University of Massachusetts, Amherst.